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Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
9 
Diagnosis: Laboratorial Investigation and 
Imaging Methods 
José Fernando Vilela-Martin and Luciana Neves Cosenso-Martin 
State Medical School of São José do Rio Preto (FAMERP), São Paulo,  
Brazil 
1. Introduction  
Pheochromocytomas and paragangliomas are rare catechomine-producing tumors. 
Pheochromocytoma is a chromaffin tumor originating in the adrenal medulla and 
paraganglioma is originating in the sympathetic and parasympathetic portions of the 
autonomic nervous system paraganglia. The patients’ symptoms are variable according the 
tumor secretion of norepinephrine (NE), epinephrine (E) or dopamine into the circulation. 
Patients with tumors predominantly secrete norepinephrine present with severe and 
refractory hypertension to conventional treatment. Patients with predominantly epinephrine 
and dopamine-secreting tumors present with episodic symptoms such as tachycardia with 
palpitations, panic attacks and feelings of doom.  
1.1 Multiple Endocrine Neoplasia syndromes (MEN) 
MEN 1 is a rare autosomal dominant disease that consists of tumors of the parathyroid 
glands, pancreatic islets (insulinomas) and anterior pituitary. Pheochromocytoma is not a 
feature in this syndrome. 
MEN 2 is an autosomal dominant syndrome with three recognized sub-types: MEN 2A, B 
and C. In MEN 2A (Sipple’s syndrome), medullary thyroid carcinoma is associated with 
pheochromocytoma and hyperparathyroidism. Pheochromocytoma is frequently bilateral 
and the diagnosis is later than medullary carcinoma. Patients who have been treated for 
medullary carcinoma should be screened for pheochromocytoma.  
2. Epidemiology 
The prevalence of pheochromocytoma is not precisely known. However, the incidence is 
about 1-2 per 100,000 adults per year according study in Minnesota (Beard et al., 1983). In 
countries other than United States, a lesser incidence has been noted about 2 to 8 cases per 
million inhabitants per year (Stenström  & Svärdsudd, 1986). In a large series of patients 
screened biochemically for suspicion of pheochromocytoma, the incidence has been 
described to be as high as 1.9%. There was no difference between men and women (Smythe 
et al., 1992). Recently, a clinical review described the incidence between 2 and 8 cases per 
million per year in the United States (Golden et al., 2009). In an autopsy series described by 
McNeil et al. one pheochromocytoma occurred per 2301 autopsies (McNeil et al., 2000). With 
the routine use of computerized tomography (CT) for abdominal complaints, it is likely that 
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more tumors will be discovered. The tumor is discovered incidentally in approximately 10% 
of patients during CT or magnetic resonance imaging (MRI) of the abdomen for unrelated 
symptoms (Kudva et al., 2003). However, recently others authors reported a 30% rate of 
incidentally discovered pheochromocytomas in their cohort of patients (Kopetschke et al., 
2009; Shen et al., 2010). Pheochromocytoma is present in 0.1% to 1% of patients with 
hypertension (Omura et al., 2004)  
Approximately 10% of adrenal pheochromocytomas and 30% of paragangliomas are 
considered malignant (Suh et al., 2009). 70% to 80% of pheochromocytomas occur 
sporadically. The familial syndromes that may present with pheochromocytoma include 
multiple endocrine neoplasia type 2 (NEM 2), von Hippel-Lindau syndrome, Osler-Weber-
Rendu syndrome, and neurofibromatosis syndrome type 1 (Guerrero et al., 2009).  The peak 
incidence occurs in the third to fifth decades of life and the average age at diagnosis is 43.9 
years in sporadic cases (Neumann et al., 2002). However, the familial syndromes include 
younger patients (24.9 years), extra-adrenal and multiple tumors and the hypertension is 
persistent (Perel et al., 1997). Some authors studied genetic screening in pheochromocytoma 
and found younger patients with familial syndromes in their cohorts (Manelli et al., 2009; 
Cascon et al., 2009). 
Pheochromocytoma was the most frequent indication for adrenalectomy (23.2%) noted by 
Villar (Villar et al., 2010).  
The 10% rule is no longer applied. The ectopic pheochromocytoma is more prevalent than 
10% (Madani et al., 2007). Extra-adrenal tumors are extra-adrenal paragangliomas and the 
majority is located in the head and neck area (69%), followed by intra-abdominal (22%) and 
intrathoracic locations (10%) (Van Der Horst-Schrivers et al., 2010). The periaortic, pericaval 
regions and Zuckerkandl’s were the commonest sites of abdominal paragangliomas 
(Erickson et al., 2001). 
3. Pathophysiology 
3.1 The sympathetic nervous system (SNS) 
The hypertension of pheochromocytoma has been thought to result solely from the action of 
circulating catecholamines on cardiovascular adrenergic receptors. However, according to 
the studies of Bravo et al., blood pressure demonstrates no correlation with circulating 
catecholamines (Bravo et al., 1979). Bravo and collaborators related that sympathetic reflexes 
are intact, and blood pressure and heart rate are significantly reduced by clonidine despite 
maintained high circulating catecholamine (Bravo et al., 1982). 
In pheochromocytoma patients, the SNS activity is enhanced and maintains the elevated 
blood pressure by the catecholamine-induced hypertension. The paradoxical elevation of 
sympathetic activity during elevation of circulating catecholamine is postulated to be due 
three mechanisms: 1) loading of sympathetic vesicles with catecholamine, presumably 
reflecting a loading of noradrenergic terminal vesicles with neurotransmitter; 2) increased 
sympathetic neuronal impulse frequency; and 3) a selective desensitization of presynaptic α2 
–adrenergic receptors. These receptors inhibit release of neuronal NE. Thus, selective 
desensitization results in enhanced release of neuronal NE during nerve stimulation.  
The hypertensive crisis could be produced by any direct or reflexly mediated stimulus to the 
SNS, because of the enhanced SNS activity and excessive stores of NE in sympathetic nerve 
terminals (Bravo & Tagle, 2003). 
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3.2 The neurohumoral agents 
Angiotensin II has no direct role in pheochromocytoma, because the administration of 
clonidine reduces arterial blood pressure without significantly decreasing plasma renin 
activity (Bravo et al., 1982). Neuropeptide Y (NPY) levels are increased in plasma and in 
tumors of patients with pheochromocytoma (deS Senanayake et al., 1995; Lundberg et al., 
1986). NPY increases coronary and peripheral and vascular resistance independently of α-
adrenergic mechanisms by interacting with vascular G protein-coupled receptors (O’Hare & 
Schwartz, 1989; Lundberg et al., 1982). The hypertensive episodes that occur in 
pheochromocytoma patients receiving α-blockade might be due the NPY release by the 
pheochromocytoma.  
3.3 Hemodynamic characteristics 
Pheochromocytoma patients have hemodynamic features similar to patients with essential 
hypertension. Thus, increased peripheral vascular resistance seems to be primarily 
responsible for maintenance of hypertension (Bravo & Tagle, 2003).  
4. Diagnosis 
Before discussing the role of laboratory diagnosis and research of imaging methods would 
be interesting to present the patient with symptoms of pheochromocytoma and the reasons 
would lead to further investigation. The table 1 shows the main points of clinical 
presentation for screening of pheochromocytoma. In addition, the table 2 shows the main 
differential diagnosis (Young & Sheps, 2008). 
 
 
 
 
 
 
Episodic symptoms of headaches, tachycardia, and diaphoresis 
Remember the five “H” characterizing pheochromocytoma: hypertension, 
hyperglycemia, hypermetabolism, hyperhidrosis and headache 
Family history of pheochromocytoma or a MEN syndrome, VHL, or neurofibromatosis 
type 1 
Incidental adrenal or abdominal masses  
Unexplained paroxysms of tachyarrhythmias, bradyarrhythmias and /or hypertension 
during intubation, induction of anesthesia, parturition, or prolonged and unexplained 
hypotension after an operation 
Adverse cardiovascular responses to ingestion, inhalation or injection of certain drugs 
(anesthetic agents, histamine, glucagons, naloxone, antidopaminergic agents, tricyclic 
antidepressants) 
Attacks occurring during exertion, turning the torso, coitus, or micturition. 
 
 
 
Table 1. Patients for screening of pheochromocytoma. 
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Endocrine 
 Thyrotoxicosis 
 Primary hypogonadism (e.g, menopausal syndrome) 
 Pancreatite tumors (e.g., insulinoma) 
 Medullary thyroid carcinoma 
 “Hyperadrenergic” spells 
Cardiovascular 
 Essential hypertension, labile 
 Angina and cardiovascular deconditioning 
 Pulmonary edema 
 Dilated cardiomyopathy 
 Syncope 
 Orthostatic hypotension 
 Paroxysmal cardiac arrhythmia 
 Aortic dissection 
 Renovascular hypertension 
Psychological 
 Anxiety and panic attacks 
 Somatization disorder 
 Hyperventilation 
 Factitious (e.g., drugs, Valsalva) 
Pharmacologic 
 Withdrawal of adrenergic-inhibiting medication (e.g, clonidine) 
 Monoamine oxidase inhibitor treatment and concomitante ingestion of tyramine or a 
decongestant 
 Sympathomimetic ingestion 
 Ilicit drug ingestion (e.g, cocaine, phencyclidine, lysergic acid) 
 Acrodynia (Mercury poisoning) 
 Vancomycin (red man syndrome) 
Neurologic 
 Baroreflex failure 
 Postural orthostatic tachycardia syndrome  
 Autonomic neuropathy 
 Migraine headache 
 Diencephalic epilepsy  (autonomic seizures) 
 Cerebral infarction 
 Cerebrovascular insufficiency 
Miscellaneous 
 Mastocytosis (systemic or activation disorder) 
 Carcinoid syndrome 
 Recurrent idiopathic anaphylaxis 
 Unexplained flushing spells 
 
 
Table 2. Differential diagnosis of pheochromocytoma. 
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Approximately 50% of pheochromocytomas produce excessive amounts E and NE and the 
other 50% predominantely produce NE. Sympathetic paragangliomas produce mainly NE, 
frequently dopamine, and never E (Eisenhofer et al., 2003).  
Measurements of fractionated metanephrines in urine and in plasma or both are the initial 
testing for pheochromocytoma (Lenders et al., 2002) and no single analysis can achieve 100% 
accuracy for pheochromocytoma diagnosis. 
When the presence of a pheochromocytoma appears likely but with equivocal biochemical 
testing, a clonidine test is recommended to distinguish true from false positives results 
(Eisenhofer et al., 2003). 
Levels of normetanephrine, metanephrine, or both metabolites are increased in almost all 
patients with pheochromocytoma. However, in small or microscopic tumors (<1 cm) 
producing small amounts of catecholamines, the levels of normetanephrine and 
metanephrine might be normal (Eisenhofer et al., 1999; Lenders et al., 2002). If there is a 
hereditary predisposition or a previous history for pheochromocytoma, a testing at a later 
date remains mandatory. False-negative results also could include patients with 
pheochromocytoma that do not produce NE or E, a more rare exception (Sawka et al., 2003).  
4.1 Plasma metanephrines 
Normal plasma levels of normetanephrine and metanephrine exclude pheochromocytoma, 
and no immediate testing for the tumor should be necessary. Thus, measurements of plasma 
free metanephrines eliminate false-negative in the diagnosis of pheochromocytoma. In 
contrast, false-positive results remain a common problem, potentially time-consuming and 
expensive for follow-up. Plasma free metanephrines sensitivity is 99%, followed closely by 
urinary fractionated metanephrines at 97% (Lenders et al., 2002). The blood sample should 
be obtained in the supine position. The technique involves the determination of free 
metanephrines in plasma by high-performance liquid chromatography (HPLC). An 
elevation of at least four times the upper reference intervals is associated with nearly a 100% 
probability of pheochromocytoma or sympathetic paraganglioma (Lenders et al., 2005). 
Elevated catecholamine and metanephrine levels by one to three times the upper limits of 
normality are usually due to various medications or physiological responses. For tests of 
plasma free metanephrines the specificity is 89% (Bravo & Tagle, 2003). 
False-positive results include medical conditions, medications, inappropriate sampling 
conditions, and diet. An overnight fast and resting supine before blood sampling minimize 
the problem. Phenoxybenzamine and tricyclic antidepressants accounted for up to 45% of 
false-positive elevations of plasma or urinary norepinephrine and normetanephrine 
(Eisenhofer et al., 2003). However, selective serotonin reuptake inhibitors may provide an 
alternative medication because they are not a cause of false-positive results. 
Phenoxybenzamine is a nonspecific α-adrenoreceptor blocker, causing norepinephrine and 
normetanephrine elevation by attenuating α2-adrenoreceptor-mediated feedback inhibition 
of norepinephrine release, possibly combined with reflexive sympathetic activation. Thus, 
this drug should be avoided until biochemical testing is complete. Alternative medications 
for blood pressure control may include calcium channel blockers and selective α1-
adrenoreceptor blockers such as doxazosin and prazosin. Non-selective α-adrenoreceptor 
blockers were associated with 60% of all false-positive elevations of plasma metanephrine. 
Nevertheless, the false-positive rate was not high (12.5%). Only if an equivocal result has 
been obtained, it is necessary repeat testing after withdrawing these medications. 
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4.2 Urinary free catecholamines and metabolites 
Urinary free NE and E and two major metabolites of the catecholamines, metanephrines 
(normetanephrines and metanephrines) and vanillylmandelic acid (VMA) are relatively easy 
to perform and are usually readly available. A diagnosis can be confirmed or excluded on 
the basis of properly collected 24h urine samples (Mannelli, 1989). In MEN syndromes, 
either 24-h urinary excretion or the calculated ratio of E to NE is a very sensitive screening 
test (Gagel et al, 1988). The sensitivity of the tests used to detect pheochromocytoma is as 
follows: urinary NE 86%, urinary E 33%, urinary VMA 64%, plasma NE 58%, and plasma E 
33%. Among all tests for pheochromocytoma, the higher specificities are 95 % for test of 
urinary VMA and 93% for test of urinary total metanephrines (Bravo & Tagle, 2003). The 
table 3 shows the sensitivity and specificity values of diagnostic tests.  
 
 
Sensitivity %                 
Hereditary       Sporadic 
Specificity % 
Hereditary       Sporadic 
Plasma 
Free Metanephrines 97 99 96 82 
Catecholamines 69 92 89 72 
Urine 
Metanephrines 96 97 82 45 
Catecholamines 79 91 96 75 
Total Metanephrines 60 88 97 89 
Vanilmandelic acid 46 77 99 86 
Table 3. The sensitivity and specificity values of diagnostic tests. 
4.3 Patterns of biochemical test results 
Patients with pheochromocytoma usually have larger relative increases in metanephrines 
than catecholamines, whereas patients with false-positive results due sympathoadrenal 
activation usually have larger increases in catecholamines than metanephrines. These 
differences are possible because pheochromocytoma tumor cells produce metanephrines 
continuously and release into the circulation independently of variations in release of the 
parent catecholamines (Eisenhofer et al., 1998).  
A plasma normetanephrine to NE ratio above 0.52 or a metanephrine to E ratio above 4.2 can 
provide confirmatory evidence of pheochromocytoma in up to 30% of patients where increases 
in plasma metanephrines are insufficient to prove the tumor (Eisenhofer et al., 2003). 
4.4 Clonidine-suppression testing 
This test was introduced by Bravo et al. (Bravo et al., 1981) to distinguish patients with 
pheochromocytoma from those with false-positive biochemical results. Decreases in 
elevated NE concentrations after clonidine suggest sympathetic activation, whereas a lack of 
decrease suggests pheochromocytoma. However, normal suppression occurs and this test is 
recommended for patients with plasma catecholamine levels over 1000 ng/liter (5.9 
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nmol/liter), with a normal response defined as a fall to within normal range (Bravo & 
Gifford, 1984). 
Another criterion for a normal response has been a fall in plasma NE after clonidine of 
more than 50% in patients with normal or only mildly elevated plasma NE levels (Bravo & 
Tagle, 2003). Plasma normetanephrine is better than NE as end-point marker for the 
clonidine-supression test, because pheochromocytomas cause larger, more consistent, and 
less episodic increases of plasma normetanephrine than NE. 76% of plasma 
normetanephrine is derived from NE released by sympathetic nerves while 90% of 
circulating metanephrine is normally derived from metabolism of E within adrenal 
chromaffin cells. Lack of decrease of plasma normetanephrine combined with a high 
plasma level after clonidine establishes high probability of pheochromocytoma. Plasma 
normetanephrine concentrations remained elevated after clonidine in 96% of patients with 
pheochromocytoma compared with only 67% for NE. (Bravo et al., 1981; Eisenhofer et al., 
2003). 
4.5 Imaging 
Computed tomography (CT) and magnetic resonance imaging (MRI) are sensitive studies 
and are recommended for initial tumor localization. MRI is preferred for children, pregnant 
or lactating women, anyone who expresses concern about excessive radiation exposure, and 
individuals who have had previous surgical resection in abdominal, pelvic, and thoracic 
cavities. The tumor diameter in majority of pheochromocytomas is greater than 2 cm, thus it 
is possible diagnose them by CT. The CT sensibility for pheochromocytoma diagnosis is 
about 90%. However, CT is less sensitive in small tumors. The MRI has a sensibility of 95% 
for the adrenal tumor bigger than 0.5 cm (Timmers et al., 2009). 
Functional imaging agents that target the catecholamine synthesis, storage, and secretion 
pathways of chromaffin tumor cells are currently used. These techniques include 123/131 
metaiodobenzylguanidine (MIBG) scintigraphy, 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine 
(DOPA) positron emission tomography (PET), and 6-[18F]fluorodopamine (FDA) PET. 
Another modality for localization of metastatic paraganglioma is the 2-[18F]fluoro-2-deoxy-
D-glucose (FDG) PET, that is less tissuspecific than the other functional approaches 
(Timmers et al., 2009). 
The 123I-metaiodobenzylguanidine (MIBG) scan has better specificity than CT and MRI, 
however it is less sensitive in the context of familial paraganglioma syndrome, 
paragangliomas, and metastatic disease. 123I-MIBG is preferred over 131I-MIBG because of its 
higher sensitivity, lower radiation exposure, and improved imaging quality with single-
photon emission-computed tomography (Timmers et al., 2009). Previous studies suggest a 
sensitivity of 123I-MIBG scintigraphy of 92-98% for nonmetastatic paraganglioma and 57-79% 
for metastases (Van Der Horst-Schrivers et al., 2006). Recently a study confirmed that the 
sensitivity is high for primary tumors and relatively poor (50%) for metastases (Timmers et 
al., 2009). 
Non-metastatic paragangliomas are well localized by these techniques described previously 
according to Timmers and collaborators (Timmers et al., 2009). However, for the detection of 
metastases seen on CT, 18F-FDA-PET was superior to 18F-DOPA-PET and 123I-MIBG 
scanning. 18F-FDG-PET is superior in evaluating metastatic paraganglioma with mutations 
in succinate dehydrogenase subunit B (SDHB), whereas 18F-DOPA-PET performs best in 
non-SDHB patients (Timmers et al., 2007). The figure 1 shows the algorithm for biochemical 
and radiological diagnosis of pheochromocytoma. 
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Fig. 1. The algorithm for biochemical and radiological diagnosis of pheochromocytoma. 
4.6 Genetics 
In actuality, 17 - 35% of pheochromocytomas and paragangliomas have a hereditary 
background. These hereditary tumors have been described in patients with 
neurofibromatosis type 1 (NF1), von Hippel Lindau syndrome (VHL), multiple endocrine 
neoplasia type 2 (MEN 2), and paraganglioma/ pheochromocytoma syndromes types 1-4 
(PGL1, PGL2, PGL3, and PGL4) (Gill et al., 2011). The mutated genes are, respectively, 
NF1, VHL, RET proto-oncogene (Rearranged in Transfection), and subunits of the enzyme 
succinate dehydrogenase (SDHD, SDH5, SDHC, and SDHB) (Gimenez-Roqueplo et al., 
2003). Hereditary pheochromocytomas and paragangliomas can be found at any age. 
However, most of these tumors are diagnosed in people younger than 50 years of age 
(Eisenhofer et al., 2011a). The most prevalent among these syndromes is PGL 1, caused  
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by germline SDHD mutations, followed by PGL 4, whereas PGL 3 is rare (Amar et al.,  
2005). 
The genetic screening should be considered in patients with history for paraganglial tumors, 
multiple tumors, young age at diagnosis, malignant pheochromocytoma because the 
prognosis in carriers of SDHB mutations is worse compared with non-SDHB-positive ones 
(Jiménez et al., 2006). Identification of a patient as a carrier of a germline mutation should be 
as early as possible. Mutation analysis of NF1 gene is not indicated because patients who 
have   pheochromocytoma and carry this gene mutation also have neurofibromas or other 
signs of the syndrome. In general, patients presenting with pheochromocytoma who have 
MEN 2 and a RET mutation will have a personal or family history of MEN 2 features 
(Eisenhofer et al., 2011b). Mutations of VHL, NF 1 and RET genes are rare. Therefore, 
mutation analysis of VHL, RET, and NF 1 should not be performed unless there is clear 
clinical evidence of these syndromic features in the patient and/or family (Neumann & Eng, 
2010). 
The pathological examination of surgically resected or biopsied tumor tissue or a diagnosis 
of inoperable malignant pheochromocytoma based on findings of metastatic disease by 
imaging studies is required to confirm pheochromocytoma.  
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